Spiegelmer Aptamers: Innovative Approach in Breast Cancer

Breast cancer remains one of the leading causes of cancer-related mortality among women worldwide, emphasizing the urgent need for improved diagnostic and therapeutic strategies. Aptamers which are synthetic oligonucleotides that specifically bind to target molecules, offer high affinity, low immunogenicity, and superior tumor penetration compared to antibodies. However, their clinical translation has been limited by instability in biological systems. Spiegelmers, a novel class of mirror-image aptamers composed of L-nucleotides, overcome this limitation through intrinsic nuclease resistance and prolonged serum half-life. These biostable molecules maintain high binding specificity to diverse targets, including proteins, peptides, and microRNAs, enabling applications in both diagnosis and therapy. In breast cancer, spiegelmers demonstrate strong potential for molecular imaging via MRI and PET when conjugated to fluorescent or radioactive labels, as well as for targeted drug delivery and photodynamic or photothermal therapy. Furthermore, spiegelmers can inhibit oncogenic microRNAs such as miR-155, offering new avenues for treating aggressive subtypes like triple-negative breast cancer. Despite challenges in synthesis and target range, spiegelmers represent a promising next-generation platform for theranostic applications that integrate precise diagnosis with personalized treatment, potentially revolutionizing breast cancer management.